F5: Q2 Earnings Insights

F5 (NASDAQ:FFIV) reported its Q2 earnings results on Wednesday, April 19, 2023 at 04:35 PM. Here’s what investors…

F5 (NASDAQ:FFIV) reported its Q2 earnings results on Wednesday, April 19, 2023 at 04:35 PM.

Here’s what investors need to know about the announcement.

Earnings

F5 beat estimated earnings by 4.55%, reporting an EPS of $2.53 versus an estimate of $2.42.

Revenue was up $68.95 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.14 which was followed by a 0.67% drop in the share price the next day.

Here’s a look at F5’s past performance:

Quarter Q1 2023 Q4 2022 Q3 2022 Q2 2022
EPS Estimate 2.33 2.52 2.24 2.01
EPS Actual 2.47 2.62 2.57 2.13
Revenue Estimate 700.68M 692.05M 667.49M 634.08M
Revenue Actual 700.38M 700.03M 674.49M 634.22M

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Guidance

F5 management provided guidance for FY 2023, expecting earnings between $10.9 and $11.31 per share.

To track all earnings releases for F5 visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Avanos Medical, Inc. Reports Preliminary Q4 And FY23 Financial Results; Revises Preliminary 2024 Revenue Outlook; Sees Q4 Revenue $170M-$173M Vs $179.27M Est.; FY23 Revenue $670M-$673M Vs $679.27M Est. ; FY24 Revenue $685M-$705M Vs $714.43M Est.

Avanos Medical, Inc. (NYSE:AVNS) today reported selected, unaudited preliminary financial results for the fourth quarter and full-year ended December 31, 2023 and revised its preliminary revenue outlook for

AVNS